Management of hepatic encephalopathy: Focus on antibiotic therapy

Digestion

Volumn 73, Issue SUPPL. 1, 2006, Pages 94-101

  Festi, Davide ^a,b   Vestito, Amanda ^a   Mazzella, Giuseppe ^a   Roda, Enrico ^a   Colecchia, Antonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Ammonia; Antibiotics; Benzodiazepine; Hepatic encephalopathy; Liver cirrhosis; Non absorbable disaccharides; Rifaximin

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; DISACCHARIDE; DOPAMINE RECEPTOR BLOCKING AGENT; LACTITOL; LACTULOSE; METRONIDAZOLE; NEOMYCIN; PAROMOMYCIN; RIFAMYCIN; RIFAXIMIN; VANCOMYCIN;

ABDOMINAL DISCOMFORT; AEROBIC BACTERIA; ALKALOSIS; ANAEROBIC BACTERIUM; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EEG ABNORMALITY; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HELICOBACTER PYLORI; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOXIA; LONG TERM CARE; MALABSORPTION; NEPHROTOXICITY; NEUROTOXICITY; NUTRITIONAL SUPPORT; OTOTOXICITY; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DIET; QUALITY CONTROL; REVIEW; UNSPECIFIED SIDE EFFECT; UREMIA; VOMITING;

ANTI-INFECTIVE AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; RIFAMYCINS; TREATMENT OUTCOME;

EID: 33644505215     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089784     Document Type: Review

References (69)

1. Blei AT, Cordoba J: Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-1976.
2. Hofnagle JH, Carithers RL Jr, Shapiro C, Ascher N: Fulminant hepatic failure: summary of a workshop. Hepatology 1995;21:240-252.
3. Mullen KD, Dasarathy S: Hepatic encephalopathy; in Schiff ER, Sorrell ME, Maddney WC (eds): Schiff's Diseases of the Liver, vol I. Philadelphia, Lippincott-Raven, 1999, pp 545-581.
4. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei A: Hepatic encephalopathy - Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna 1998. Hepatology 2002;35:716-721.
5. Mas A: Hepatic encephalopathy: from pathophysiology to treatment. Digestion 2005;73(suppl 1):78-85.
6. Teasdale G, Knill-Jones R, van der Sande J: Observer variability in assessing impaired consciousness and coma. J Neurol Neurosurg Psychiatry 1978;41:603-610.
7. Ong JP, Mullen KD: Hepatic encephalopathy. Eur J Gastroenterol Hepatol 2001;13:325-334.
8. Lizardi-Cervera J, Almeda P, Guevara L, Uribe M: Hepatic encephalopathy: a review. Ann Hepatol 2003;2:122-130.
9. Butterworth RF: The neurobiology of hepatic encephalopathy. Semin Liver Dis 1996;16:235-244.
10. Norenberg MD: Astrocytic-ammonia interactions in hepatic encephalopathy. Semin Liver Dis 1996;16:245-253.
11. Lockwood AH, Yap EW, Wong WH: Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991;11:337-341.
12. Butterworth RE, Giguere JF, Michaud J, Lavoie J, Layragues GP. Ammonia: a key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987;6:1-12.
13. Norenberg MD: Astroglial dysfunction in hepatic encephalopathy. Metab Brain Dis 1998;13:319-335.
14. Rao VL, Butterworth RE: Neuronal nitric oxide synthase and hepatic encephalopathy. Metab Brain Dis 1998;13:175-189.
15. A receptor complex by ammonia: implications for the pathogenesis of hyperammonemic syndromes. Brain Res 1996;720:35-44.
16. Basile AS, Jones EA: Ammonia and GABAergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997;25:1303-1305.
17. Mullen KD. Benzodiazepine compounds and hepatic encephalopathy. N Engl J Med 1991;325:509-511.
18. Mullen KD, Jones EA: Natural benzodiazepines and hepatic encephalopathy. Semin Liver Dis 1996;16:225-264.
19. Yurdaydin C, Walsh TJ, Engler HD, Ha JH, Li Y, Jones EA, Basile AS: Gut bacteria provide precursor of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. Brain Res 1995;679:42-48.
20. Avallone R, Zeneroli ML, Venturini I, Corsi L, Schreier P, Kleinschnitz M, Ferrarese C, Farina F, Baraldi C, Pecora N, Frigo M, Baraldi M: Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrhosis with and without overt encephalopathy. Gut 1998;42:861-867.
21. Zieve L, Doizaki WM, Zieve J: Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 1974;83:16-28.
22. Rose C, Butterworth RF, Zayed J: Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999;117:640-644.
23. Aronson LR, Gacad RC, Kaminsky-Russ K, Gregory CR, Mullen KD: Endogenous benzodiazepine activity in the peripheral and portal blood of dogs with congenital portosystemic shunts. Vet Sug 1997;26:189-194.
24. Hernandez-Avila CA, Shoemaker WJ, Ortega-Soto HA: Plasma concentrations of endogenous benzodiazepine-receptor ligands in patients with hepatic encephalopathy: a comparative study. J Psychiatry Neurosci 1998;23:217-222.
25. Barbara G, Di Lorenzo G, Soldini M, Marziali M, Bellomo G, Belloni G: Flumazenil for hepatic encephalopthy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998;28:374-378.
26. Abou-Assi S, Vlahcevic ZR: Hepatic encephalopathy: metabolic consequence of cirrhosis often is reversible. Postgrad Med 2001;109:52-70.
27. Córdoba J, Blei AT: Treatment of hepatic encephalopathy. Am J Gastroenterol 1997;92:1429-1439.
28. Morgan MY: The treatment of chronic hepatic encephalopathy. Hepatogastroenterology 1991;38:377-387.
29. Riordan SM, Williams R: Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473-479.
30. Fast BB, Wolfe SJ, Stormont JM, Davidson CS: Antibiotic therapy in the management of hepatic coma. AMA Arch Intern Med 1958;101:467-475.
31. Conn HO, Leavy CM, Vlahcevic ZR, Rodgers JB, Maddrey WB, Seeff L: Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double-blind controlled trial. Gastroenterology 1977;72:573-583.
32. Orlandi F, Freddara U, Candelaresi MT, Morettini A, Corazza GR, Di Simone A: Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 1981;26:498-506.
33. Koshy A, Ayyagari A, Bharati G, Goyal AK, Kaur U: Relative efficacy of neomycin and ampicillin against urease producing organisms. Indian J Med Res 1981;74:486-488.
34. Meyers S, Lieber CS: Reduction of gastric ammonia by ampicillin in normal and azotemic subjects. Gastroenterology 1976;70:244-247.
35. Alexander T, Thomas K, Cherian AM, Kanakasabapathy: Effect of three antibacterial drugs in lowering blood and stool ammonia production in hepatic encephalopathy. Indian J Med Res 1992;96:292-296.
36. Tromm A, Griga T, Greving I, Hilden H, Huppe D, Schwegler U, Micklefield GH, May B: Orthograde whole gut irrigation with mannite versus paromomycine + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Hepatogastroenterology 2000;47:473-477.
37. Morgan MH, Read AE, Speller DC: Treatment of hepatic encephalopathy with metronidazole. Gut 1982;23:1-7.
38. Als-Nielsen B, Gluud LL, Gluud C: Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. Br Med J 2004;328:1046-1052.
39. Chambers JF, Sande MA: The aminoglycosides; in Hardman JG, Limbird LE, Molinoff PB, et al (eds): Goodman and Gilman's the Pharmacological Basis of Therapeutics, ed 9. New York, McGraw-Hill, 1995, pp 1103-1121.
40. Green PHR, Tall AR: Drugs, alcohol and malabsorption. Am J Med 1979;67:1066-1076.
41. Faloon WW: Metabolic effects of nonabsorbable antibacterial agents. Am J Clin Nutr 1970;23:645-651.
42. Tracy JW, Webster LT: Drugs used in the chemotherapy of protozoal infections; in Hardman JG, Limbird LE (eds): Goodman & Gilman's the Pharmacological Basis of Therapeutics, ed 10. New York, McGraw-Hill, 2001, pp 1097-1120.
43. Uhl MD, Riely CA: Metronidazole in treating portosystemic encephalopathy. Ann Intern Med 1996;124:455.
44. Kim KH, Choi JW, Lee JY, Kim TD, Paek JH, Lee EJ, Oh HA, Kim JH, Jang BI, Kim TN, Chung MK, Lee HJ, Byun WM: Two cases of metronidazole-induced encephalopathy (in Korean). Korean J Gastroenterol 2005;45:195-200.
45. Scarpignato C, Pelosini I: Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(suppl 1):36-66.
46. Baker DE: Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord 2005;5:19-30.
47. Festi D, Mazzella G, Orsini M, Sottili S, Sangermano A, Li Bassi S, Parini P, Ferrieri A, Falcucci M, Grossi L, Marzio L, Roda E: Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 1993;54:598-609.
48. Williams R, Bass N: Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. Rev Gastroenterol Disord 2005;5(suppl 1):10-18.
49. Zeneroli ML, Avallone R, Corsi L, Venturini I, Baraldi C, Baraldi M: Management of hepatic encephalopathy: role of rifaximin. Chemotherapy 2005;51(suppl 1):90-95.
50. De Marco F, Santamaria Amato P, D'Arienzo A: Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. Curr Ther Res 1984;36:668-674.
51. Testa R, Eftimiadi C, Sukkar GS, De Leo C, Rovida S, Schito GC, Celle G: A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985;11:387-392.
52. Di Piazza S, Filippazzo MG, Valenza LM, Morello S, Pastore L, Conti A, Cottone S, Pagliaro L: Rifaximin versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991;23:403-407.
53. Pedretti G, Calzetti C, Missale G, Fiaccadori F: Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991;23:175-178.
54. Parini P, Cipolla A, Ronchi M, Salzetta A, Mazzella G, Roda E: Effect of rifaximin in the treatment of portal-systemic encephalopathy. Curr Ther Res 1992;52:34-39.
55. Fera G, Agostinacchio F, Nigro M, Schiraldi O, Ferrieri A: Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993;4:57-66.
56. Bucci L, Calmieri GC: Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993;13:109-118.
57. Massa P, Vallerino E, Dodero M: Treatment of hepatic encephalopathy with rifaximin: double-blind, double-dummy study versus lactulose. Eur J Clin Res 1993;4:7-18.
58. Puxeddu A, Quartini M, Massinetti A, Ferrieri A: Rifaximin in the treatment of chronic hepatic encephalopathy. A double-blind randomised trial. Curr Med Res Opin 1995;13:274-281.
59. Miglio F, Valpiani D, Rosselli SR, Ferrieri A: Rifaximin, a non-absorbable rifamycin, for hepatic encephalopathy. A double-blind randomised trial. Curr Med Res Opin 1997;13:593-601.
60. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C: Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Min Gastroenterol Dietol 2003;49:53-62.
61. Williams R, James O, Warnes TW, Morgan MY: Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000;12:203-208.
62. Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodriguez-Martinez D, Fernandez-Rodriguez C, Coll I, Pardo A: Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:51-58.
63. Sama C, Morselli-Labate AM, Pianta P, Lambertini L, Berardi S, Martini G: Clinical effects of rifaximin in patients with encephalopathy intolerant or non-responsive to previous lactulose treatment: an open-label, pilot study. Cur Ther Res 2004;65:413-422.
64. Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, Chon CY, Lee SI, Moon YM: Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005;46:399-407.
65. Zeneroli ML, Venturini I, Stefanelli S, Farina F, Cosenza R, Miglioli L, Minelli E, Amedei R, Ferrieri A, Avallone R, Baraldi M: Antibacterial activity of rifaximin reduces the levels of benzodiazepine-like compounds in patients with liver cirrhosis. Pharmacol Res 1997;35:557-600.
66. Unseld E, Klotz U: Benzodiazepines: are they of natural origin? Pharmacol Res 1989;6:1-3.
67. Yurdaydin C, Walsh TJ, Howard DE, Ha J, Li Y, Jones EA, Basile AS: Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. Brain Res 1995;679:42-48.
68. Lighthouse J, Naito Y, Helmy A, Hotten P, Fuji H, Min CH, Yoshioka M, Marotta F: Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: a randomized study comparing the effect of rifaximin alone and association with a symbiotic preparation. Hepatol Res 2004;28:155-160.
69. Leevy CB, Philips JA: A crossover retrospective chart review evaluating hospitalization associated with the use of rifaximin vs. lactulose in the management of patients with hepatic encephalopathy. Am J Gastroenterol 2005;100(suppl):S134.